Hector Sanchez, MD
Internal Medicine · Wilmington, NCNPI 1124446513
Payments from drug & device makers
Across 416 payments — averaging $1851.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$310K
- AstraZeneca$295K
- GSK$82K
- Sanofi$29K
- Amgen$20K
- Boehringer Ingelheim$15K
- plus $19K from 29 others
Across 1 payment — averaging $956.69 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$957
What the payments were for
- Consulting fees$1,5151%
- Speaking & faculty fees$161,51984%
- Travel & lodging$19,18510%
- Food & beverage$10,6866%
- Education$2500%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 8 | $309,577 |
| AstraZeneca | 138 | $295,263 |
| GSK | 62 | $81,734 |
| Sanofi | 30 | $28,818 |
| Amgen | 28 | $20,353 |
| Boehringer Ingelheim | 34 | $15,329 |
| Verona Pharma, Inc. | 23 | $15,088 |
| Teva Pharmaceuticals USA, Inc. | 4 | $1,450 |
| Astrazeneca UK Limited | 1 | $500 |
| United Therapeutics Corporation | 7 | $391 |
| Regeneron Healthcare Solutions, Inc. | 16 | $348 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $231 |
| Jazz Pharmaceuticals Inc. | 5 | $167 |
| Pulmonx Corporation | 8 | $165 |
| ANI Pharmaceuticals, Inc. | 7 | $129 |
| Merck | 5 | $106 |
| Sanofi-aventis U.S. LLC | 1 | $100 |
| Insmed, Inc. | 5 | $96 |
| Actelion Pharmaceuticals US, Inc. | 3 | $74 |
| Mylan Specialty L.p. | 3 | $65 |
| Grifols USA, LLC | 3 | $60 |
| Grifols Shared Services North America, Inc. | 1 | $58 |
| Gilead | 2 | $46 |
| Medtronic | 2 | $42 |
| Viatris Specialty LLC | 2 | $41 |
| Resmed Corp | 1 | $31 |
| Stryker | 1 | $25 |
| Pfizer | 1 | $24 |
| Otsuka America Pharmaceutical, Inc. | 1 | $18 |
| Inogen, Inc. | 1 | $17 |
| Boston Scientific | 1 | $15 |
| Paratek Pharmaceuticals, Inc. | 1 | $14 |
| Johnson & Johnson | 1 | $12 |
| Veran Medical Technologies, Inc. | 1 | $12 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$770,409 in reported general payments places this provider in the 95th percentile of 3,302 internal medicine providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 19 | $245,673 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 262 | $223,674 |
| TezspireTezepelumab-Ekko | 46 | $194,400 |
| GlassiaAlpha-1-Proteinase Inhibitor | 12 | $120,902 |
| Dupixent PenDupilumab | 28 | $111,878 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 106 | $73,175 |
| Breo ElliptaFluticasone/Vilanterol | 100 | $51,993 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 79 | $45,069 |
| Spiriva RespimatTiotropium Bromide | 65 | $40,259 |
| NucalaMepolizumab | 11 | $37,899 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 73 | $35,956 |
| SymbicortBudesonide/Formoterol Fumarate | 82 | $23,603 |
| Incruse ElliptaUmeclidinium Bromide | 20 | $11,380 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 26 | $7,647 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 206 | $5,562 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Nucala, Anoro Ellipta, Incruse Ellipta | $81,734 | $360,903466 claims |
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat | $15,329 | $331,001163 claims |
| AstraZenecaTezspire, Breztri Aerosphere, Symbicort | $295,263 | $291,177234 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Glassia | $231 | $120,90212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,302 internal medicine providers in North Carolina.
Other internal medicine in Wilmington
- Brian WebsterWilmington$3.7M
- Manesh PatelDurham$27.2M
- Saad UsmaniCharlotte$16.2M
- Christina KennellyCharlotte$15.4M
- John RubinoRaleigh$13M
- Adam DevoreDurham$11.8M
- Krishnakumar UdayakumarDurham$11M
- Sylvia ShoffnerCary$7.1M
- Wayne HarperRaleigh$6.7M
- Joseph MoranStatesville$6.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.